Guggenheim Starts Neothetics Inc. (NEOT) at Buy

Go back to Guggenheim Starts Neothetics Inc. (NEOT) at Buy

Needham & Company Starts Neothetics Inc. (NEOT) at Buy

December 15, 2014 6:41 AM EST

Needham & Company initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $17.00.

Analyst Elliot Wilbur commented, "We initiate coverage of Neothetics (NEOT), a clinical-stage specialty pharma company focused on developing and commercializing innovative and differentiated... More

Piper Jaffray Starts Neothetics Inc. (NEOT) at Overweight

December 15, 2014 6:39 AM EST

Piper Jaffray initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Overweight rating and a price target of $20.00.

Analyst David Amsellem comments, "NEOT, in our view, is well positioned to expand and transform the emerging body contouring space with LIPO-202, an injectable form... More